Levels of BAFF, APRIL, IFN-γ, IL-21 and IL-10 were significantly higher in patients with aPL-positive SLE than in healthy controls and decreased after 24 weeks of telitacicept treatment. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.